Literature DB >> 23322664

An 'omics approach towards CHO cell engineering.

Payel Datta1, Robert J Linhardt, Susan T Sharfstein.   

Abstract

Chinese hamster ovarian cells (CHO) cells have been extensively utilized for industrial production of biopharmaceutical products, such as monoclonal antibodies, human growth hormones, cytokines, and blood-products. Recent advances in recombinant DNA technology have resulted in the bioengineering of CHO cells that have robust gene amplification systems and can also be adapted to grow in suspension cultures. In parallel, recent advances in techniques and tools for decoding the CHO cell genome, transcriptome, proteome, and glycome have led to new areas of study for better understanding the metabolic pathways in CHO cells with the long-term goal of developing new biologics. This review paper discusses the recent advances in bioengineering strategies in CHO cell lines and the impact of the knowledge gained by CHO cell genomics, transcriptomics, and glycomics on the future of CHO-cell engineering.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23322664     DOI: 10.1002/bit.24841

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  26 in total

Review 1.  Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.

Authors:  Matthew Ho Zhi Guang; Amanda McCann; Giada Bianchi; Li Zhang; Paul Dowling; Despina Bazou; Peter O'Gorman; Kenneth C Anderson
Journal:  Leuk Lymphoma       Date:  2017-06-13

2.  Enhanced IgG1 production by overexpression of nuclear factor kappa B inhibitor zeta (NFKBIZ) in Chinese hamster ovary cells.

Authors:  Masayoshi Onitsuka; Yukie Kinoshita; Akitoshi Nishizawa; Tomomi Tsutsui; Takeshi Omasa
Journal:  Cytotechnology       Date:  2017-11-29       Impact factor: 2.058

3.  Quality cell therapy manufacturing by design.

Authors:  Yonatan Y Lipsitz; Nicholas E Timmins; Peter W Zandstra
Journal:  Nat Biotechnol       Date:  2016-04       Impact factor: 54.908

4.  Validation and identification of reference genes in Chinese hamster ovary cells for Fc-fusion protein production.

Authors:  Xiaonan Ma; Ling Zhang; Luming Zhang; Chenglong Wang; Xiaorui Guo; Yu Yang; Lin Wang; Xiangru Li; Ningning Ma
Journal:  Exp Biol Med (Maywood)       Date:  2020-03-26

5.  Modulation of heparan sulfate biosynthesis by sodium butyrate in recombinant CHO cells.

Authors:  Payel Datta; Bo Yang; Robert J Linhardt; Susan T Sharfstein
Journal:  Cytotechnology       Date:  2014-01-29       Impact factor: 2.058

Review 6.  Heparin and related polysaccharides: synthesis using recombinant enzymes and metabolic engineering.

Authors:  Matthew Suflita; Li Fu; Wenqin He; Mattheos Koffas; Robert J Linhardt
Journal:  Appl Microbiol Biotechnol       Date:  2015-07-29       Impact factor: 4.813

7.  Genomic landscapes of Chinese hamster ovary cell lines as revealed by the Cricetulus griseus draft genome.

Authors:  Nathan E Lewis; Xin Liu; Yuxiang Li; Harish Nagarajan; George Yerganian; Edward O'Brien; Aarash Bordbar; Anne M Roth; Jeffrey Rosenbloom; Chao Bian; Min Xie; Wenbin Chen; Ning Li; Deniz Baycin-Hizal; Haythem Latif; Jochen Forster; Michael J Betenbaugh; Iman Famili; Xun Xu; Jun Wang; Bernhard O Palsson
Journal:  Nat Biotechnol       Date:  2013-07-21       Impact factor: 54.908

8.  Microarray platform affords improved product analysis in mammalian cell growth studies.

Authors:  Payel Datta; Luciana Meli; Lingyun Li; Nicole Migliore; Eugene Schaefer; Susan T Sharfstein; Jonathan S Dordick; Robert J Linhardt
Journal:  Biotechnol J       Date:  2013-12-19       Impact factor: 4.677

9.  Bioengineered Chinese hamster ovary cells with Golgi-targeted 3-O-sulfotransferase-1 biosynthesize heparan sulfate with an antithrombin-binding site.

Authors:  Payel Datta; Guoyun Li; Bo Yang; Xue Zhao; Jong Youn Baik; Trent R Gemmill; Susan T Sharfstein; Robert J Linhardt
Journal:  J Biol Chem       Date:  2013-11-18       Impact factor: 5.157

Review 10.  Bioengineered heparins and heparan sulfates.

Authors:  Li Fu; Matthew Suflita; Robert J Linhardt
Journal:  Adv Drug Deliv Rev       Date:  2015-11-10       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.